Siga Technologies Inc (SIGA): Cost of Revenue
$29.70M
Year ended 2025-12-31
$24.49M
Trailing 12 months to 2026-06-30
+41.7%
3-year compound annual growth
+15.0%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.70M | -5.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $31.29M | +75.5% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $17.83M | +70.9% | 2026-03-10, From 2023-01-01 |
| 2022-12-31 | $10.43M | -37.2% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $16.60M | +12.2% | 2024-03-12, From 2021-01-01 |
| 2020-12-31 | $14.80M | +730.0% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $1.78M | -98.1% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $95.27M | n/a | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2019-03-06, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Siga Technologies Inc (SIGA) | 2025-12-31 | $29.70M | -5.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.79M | -7.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $12.45M | +40.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $5.80M | -2.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $37.21M | +138.5% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $5.42M | +39.4% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $88.57M | +2.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.56M | -31.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $20.92M | +0.2% |
Compare SIGA, LAB, URGN, ADCT side by side · Screen every company in Pharmaceutical Preparations ↗